A pivotal phase III clinical trial evaluating the efficacy of VPM1002 as prime vaccine in newborn infants funded by Serum Institute of India Pvt. Ltd. (SIIPL) and the European & Developing Countries Clinical Trials Partnership (EDCTP) will be conducted in South Africa, Tanzania, Kenya, Uganda and Gabon. The involved parties of the trial are part of a consortium (priMe) with VPM acting as coordinator. In this framework, VPM organized a kick-off meeting for the priMe consortium aimed at fostering interaction between the consortium partners and facilitating discussions on key aspects of the trial.
News
